NCT01391962 2026-02-02
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
8 trialsNCT00942877 2025-03-03
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01062425 2022-07-26
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT01337401 2019-01-24
CASPS
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT01310855 2017-05-31
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
University College, London
Phase 2 Terminated
NCT00305656 2013-08-22
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00385203 2012-07-16
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
AstraZeneca
Phase 2 Completed